Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Bin Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9857-4293; OpenAlex author ID A5101773214. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Leucine Aminopeptidase-Responsive Bioluminescent Probe for Point-of-Care Diagnosis of Pancreatic Cancer in Blood and Urine. Co-author DOI 10.1021/acs.analchem.6c03034↗
  2. Thioketal-Incorporated Biodegradable Lipid Nanoparticles Deliver mRNA to Ductal Epithelial Cells for Improved Pancreatic Cancer Treatment. Co-author DOI 10.1021/jacs.5c19387↗
  3. LINC00960 regulates cell proliferation and glycolysis in pancreatic cancer through the miR-326-3p/TUFT1/AKT-mTOR axis. Co-author DOI 10.1002/kjm2.12594↗
  4. Immunotherapy for pancreatic cancer: A long and hopeful journey. Co-author DOI 10.1016/j.canlet.2018.03.040↗
  5. Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Co-author DOI 10.1038/s41419-018-0724-5↗
  6. Early detection of pancreatic cancer: Where are we now and where are we going? Co-author DOI 10.1002/ijc.30670↗
  7. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. First author DOI 10.1016/j.canlet.2017.01.041↗
  8. Stiehopus japonieus acidic mucopolysaccharide inhibits the proliferation of pancreatic cancer SW1990 cells through Hippo-YAP pathway. Co-author DOI 10.18632/oncotarget.14633↗
  9. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Co-author DOI 10.1016/j.canlet.2016.02.018↗
  10. TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition. Co-author DOI 10.1016/j.canlet.2016.08.017↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinyu Qiu · 2 shared papers, 2025–2026 · strength 0.56
  2. Hu Xiong · 2 shared papers, 2025–2026 · strength 0.56
  3. Jianwei Xu · 5 shared papers, 2016–2018 · strength 0.36
  4. Weidong Guo · 3 shared papers, 2016–2022 · strength 0.31
  5. Sanyuan Hu · 4 shared papers, 2016–2018 · strength 0.30
  6. Xiuchao Wang · 1 shared paper, 2026 · strength 0.29
  7. Yuehua Chen · 1 shared paper, 2026 · strength 0.29
  8. Hanxiang Zhan · 3 shared papers, 2016–2022 · strength 0.28
  9. Lei Wang · 3 shared papers, 2017–2018 · strength 0.25
  10. Hanxiang Zhan · 3 shared papers, 2016–2018 · strength 0.22
  11. Shanglong Liu · 2 shared papers, 2016–2022 · strength 0.20
  12. Guangyong Zhang · 2 shared papers, 2017–2018 · strength 0.17
  13. Jingyu Cao · 1 shared paper, 2022 · strength 0.14
  14. T. T. Qu · 1 shared paper, 2022 · strength 0.14
  15. Jing‐Hao Lei · 1 shared paper, 2022 · strength 0.14
  16. Xiao Hu · 1 shared paper, 2022 · strength 0.14
  17. Xiaoyu Li · 2 shared papers, 2016–2017 · strength 0.12
  18. Bingyuan Zhang · 1 shared paper, 2018 · strength 0.11
  19. Fang Zheng · 1 shared paper, 2018 · strength 0.11
  20. Zibin Tian · 1 shared paper, 2017 · strength 0.06
  21. Cuiping Zhang · 1 shared paper, 2017 · strength 0.06
  22. Jun Wu · 1 shared paper, 2017 · strength 0.06
  23. Qinghui Niu · 1 shared paper, 2017 · strength 0.06
  24. Lei Wang · 1 shared paper, 2016 · strength 0.06
  25. Ce Li · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.